Zymeworks to Host First Quarter 2022 Results Conference Call

Rhea-AI Summary

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will announce its Q1 2022 financial results on May 4, 2022, after market close. A conference call and webcast to discuss the results will follow at 4:30 p.m. ET. Investors can join the call by dialing 844-435-7258 (U.S. & Canada) or +1-631-485-4286 (international). Zymeworks is known for its innovative biotherapeutics, including its lead candidate, zanidatamab, a HER2-targeted bispecific antibody currently in clinical trials.

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its first quarter 2022 financial results after market close on May 4^th, 2022. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 4^th, 2022 at 4:30 p.m. ET.

Conference Call and Webcast Information:

• Telephone: 844-435-7258 (U.S. or Canada) or +1-631-485-4286 (international)
• The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005147/en/

Jack Spinks

(604) 678-1388

ir@zymeworks.com



Media Inquiries:

Diana Papove

(604) 678-1388

media@zymeworks.com

Source: Zymeworks Inc.

FAQ

When will Zymeworks report its Q1 2022 financial results?

Zymeworks will report its Q1 2022 financial results after market close on May 4, 2022.

What time is the Zymeworks conference call on May 4, 2022?

The conference call for Zymeworks will begin at 4:30 p.m. ET on May 4, 2022.

How can I access the Zymeworks conference call?

You can access the Zymeworks conference call by dialing 844-435-7258 (U.S. & Canada) or +1-631-485-4286 (international).

What is Zymeworks' lead clinical candidate?

Zymeworks' lead clinical candidate is zanidatamab, a HER2-targeted bispecific antibody.

Where can I find more information on Zymeworks' clinical trials?

More information on Zymeworks' clinical trials can be found at www.zymeworksclinicaltrials.com.